Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: A systemic inflammatory marker, the modified Glasgow prognostic score (mGPS), could predict outcomes in non-muscle-invasive bladder cancer (NIMBC). We aimed to investigate the predictive power of mGPS in oncological outcomes in HG/G3 T1 NMIBC patients undergoing Bacillus Calmette-Guérin (BCG) therapy.
Methods: We retrospectively reviewed patient's medical data from multicenter institutions. A total of 1382 patients with HG/G3 T1 NMIBC have been administered adjuvant intravesical BCG therapy, every week for 3 weeks given at 3, 6, 12, 18, 24, 30 and 36 months. The analysis of mGPS for recurrence and progression was performed using multivariable and univariable Cox regression models.
Results: During follow-up, 659 patients (47.68%) suffered recurrence, 441 (31.91%) suffered progression, 156 (11.28%) died of all causes, and 67 (4.84%) died of bladder cancer. At multivariable analysis, neutrophil to lymphocyte ratio [hazard ratio (HR): 7.471; = 0.0001] and erythrocyte sedimentation rate (ESR) (HR: 0.706; = 0.006 were significantly associated with recurrence. mGPS has no statistical significance for progression ( = 0.076). Kaplan-Meier survival analysis showed a significant difference in survival among patients from different mGPS subgroups. Five-year OS was 93% (CI 95% 92-94), in patients with mGPS 0, 82.2% (CI 95% 78.9-85.5) in patients with mGPS 1 and 78.1% (CI 95% 60.4-70) in mGPS 2 patients. Five-year CSS was 98% (CI 95% 97-99) in patients with mGPS 0, 90% (CI 95% 87-94) in patients with mGPS 1, and 100% in mGPS 2 patients. Limitations are applicable to a retrospective study.
Conclusions: mGPS may have the potential to predict recurrence in HG/G3 T1 NMIBC patients, but more prospective, with large cohorts, studies are needed to study the influence of systemic inflammatory markers in prediction of outcomes in NMIBC for a definitive conclusion.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8947693 | PMC |
| http://dx.doi.org/10.3390/diagnostics12030586 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Adverse events of pexidartinib for the treatment of TGCT: a real-world disproportionality analysis using FDA Adverse Event Reporting System database.
Front Oncol
August 2025
Department of Pharmacy, Pingtan Comprehensive Experimental Area Hospital, Fuzhou, China.
Introduction: Pexidartinib, an oral selective colony-stimulating factor 1 receptor (CSF1R) inhibitor, is the only systemic therapy approved by the U.S. Food and Drug Administration (FDA) for tenosynovial giant cell tumor (TGCT).
View Article and Find Full Text PDFComparative Prognostic Accuracy of Clinical and Inflammation- or Nutrition-Based Scores in Older Adults with Community-Acquired Pneumonia.
Int J Gen Med
August 2025
Department of Emergency Medicine, University of Health Sciences, Fatih Sultan Mehmet Education and Research Hospital, Istanbul, Turkey.
Purpose: This study aimed to assess the prognostic accuracy of the Glasgow Prognostic Score (GPS), modified Glasgow Prognostic Score (mGPS), and C-reactive protein/albumin ratio (CAR) in predicting 30-day mortality and intensive care unit (ICU) admission compared with the Pneumonia Severity Index (PSI) and CURB-65 in older adults with community-acquired pneumonia (CAP).
Patients And Methods: This retrospective, single-center cohort study was conducted in a tertiary emergency department. Patients aged ≥65 years with CAP were included.
Phase IV safety evaluation of voclosporin in lupus nephritis patients using the FAERS database for a 42-month period (2021 - 2024).
Int J Clin Pharmacol Ther
September 2025
Objective: Voclosporin, a novel calcineurin inhibitor (CNI), was FDA-approved in 2021 for treating lupus nephritis (LN). However, post-marketing studies and reports on adverse events (AEs) associated with voclosporin remain limited. This study analyzes voclosporin-associated AEs using FDA Adverse Event Reporting System (FAERS) data.
View Article and Find Full Text PDFA Real-World Disproportionality Analysis of FDA Adverse Event Reporting System(FAERS) Event for Belatacept.
Transplant Proc
August 2025
Department of Urology/ Institute of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, China; Kidney Transplantation Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China; Organ Transplantation Center, West China Hospital, Sichuan University, Chengdu, Sichuan, Chi
Objective: This study aims to comprehensively evaluate the safety profile of belatacept administration in real-world clinical settings.
Methods: Disproportionality analysis methodologies, including Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), and Multi-Item Gamma Poisson Shrinker (MGPS) algorithms, were utilized to quantify real-world adverse event (AE) signals associated with belatacept.
Results: A total of 4631 adverse event reports were extracted from the FDA Adverse Event Reporting System (FAERS) database, of which 2337 adverse events were identified as "primary suspect" (PS) attributed to belatacept.
Drug-induced gingival diseases: insights from the FDA Adverse Event Reporting System (FAERS) database analysis.
Eur J Pharmacol
August 2025
School of Stomatology, Hunan University of Chinese Medicine, Changsha, China; Department of Periodontal Mucosa, Changsha Stomatological Hospital, Changsha, China. Electronic address:
Drug-induced gingival diseases are a common clinical condition. This study aims to identify potential drugs associated with such diseases by analyzing data from the FDA Adverse Event Reporting System (FAERS) database, covering the period 2004Q1 to 2024Q3. Potential signals were detected using disproportionality analyses, including reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), and multi-item gamma Poisson shrinker (MGPS).
View Article and Find Full Text PDF